Can you take Orlistat with Panamax?

The acetaminophen in Panamax has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

Orlistat has a major potential interaction with Biliary Obstruction.

The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides. At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.

The acetaminophen in Panamax has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Panamax has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Orlistat has a major potential interaction with Malabsorption Syndrome.

The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides. At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.

The acetaminophen in Panamax has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Orlistat has a moderate potential interaction with Nephrolithiasis.

Following treatment with orlistat, some patients may develop increased levels of urinary oxalate as a result of fat malabsorption. Therapy with orlistat should be administered cautiously in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.

The acetaminophen in Panamax has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Orlistat has a moderate potential interaction with Type 2 Diabetes.

Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

Orlistat has a moderate potential interaction with Vitamin A Deficiency.

At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.

Orlistat has a moderate potential interaction with Vitamin D Deficiency.

At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.

Orlistat has a moderate potential interaction with Vitamin K Deficiency.

At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.